Atrium Therapeutics
RNA
162 hedge funds and large institutions have $198M invested in Atrium Therapeutics in 2026 Q1 according to their latest regulatory filings, with 162 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
86.6% more ownership
Funds ownership: 0% → 86.6% (+87%)
94% less call options, than puts
Call options by funds: $968K | Put options by funds: $15.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.8M |
| 2 |
BlackRock
New York
|
+$16.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.1M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$8.54M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$8.47M |
Top Sellers
RNA Hedge Fund Activity: Q1 2026 in Review
162 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Atrium Therapeutics (RNA) for Q1 2026, worth a combined $198M.
Buyers outnumbered sellers: 162 funds opened new RNA positions and 0 closed out — a net gain of 162 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $21.8M.
- 162 institutional investors held Atrium Therapeutics (RNA) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $198M of Atrium Therapeutics stock for Q1 2026.
- 162 funds opened new Atrium Therapeutics positions in Q1 2026 and 0 closed out, a net change of +162 holders.
- The largest Atrium Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $21.8M added.
Based on aggregated 13F filings for Q1 2026.